Loading...
XMEX
MEDICAB
Market cap161mUSD
Apr 04, Last price  
34.40MXN
Name

Medica Sur, S.A.B. De C.V.

Chart & Performance

D1W1MN
P/E
7.11
P/S
0.75
EPS
4.84
Div Yield, %
4.36%
Shrs. gr., 5y
-2.73%
Rev. gr., 5y
3.55%
Revenues
4.40b
+6.61%
1,057,251,0981,224,235,6481,397,174,4901,556,154,7551,784,449,4111,822,723,9751,900,834,0932,089,975,6842,256,399,6122,292,095,9952,278,751,6022,590,272,6123,431,445,8463,607,605,8393,698,067,6774,466,185,9343,906,143,7753,867,922,4284,129,753,9844,402,820,000
Net income
462m
-27.32%
144,495,381194,246,154216,324,806193,732,240236,829,900231,326,985224,088,054300,513,456379,765,048349,084,341241,018,529142,634,010231,798,220169,295,459140,551,783558,827,8221,154,516,740949,802,530634,983,587461,509,000
CFO
595m
+40.34%
230,752,691311,868,812305,416,639306,190,243427,755,325316,393,450349,721,873344,107,405494,095,240474,579,657327,807,240198,782,141213,985,864305,898,124425,440,5801,101,315,918821,320,259270,090,208423,871,328594,873,000
Dividend
May 14, 20241.5 MXN/sh
Earnings
Apr 29, 2025

Profile

Médica Sur, S.A.B. de C.V. operates as a healthcare institution in Mexico. The company offers bypass and gastric banding, cholecystectomy, inguinal hernia repair, liposculpture, breast cosmetic, stereotactic radio, hip arthroplasty, knee arthroscopy, shoulder arthroscopy, spine, lithiasis, radical prostatectomy, and prostate surgeries. It also provides radiotherapy, imaging, and checkup services, as well as medical insurance services. The company was incorporated in 1966 and is based in Mexico City, Mexico. Médica Sur, S.A.B. de C.V. is a subsidiary of Neuco, SA de CV.
URL
https://www.medicasur.com.mx/
IPO date
Mar 10, 1994
Employees
Domiciled in
MX
Incorporated in
MX

Valuation

Title
MXN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,402,820
6.61%
4,129,754
6.77%
3,867,922
-0.98%
Cost of revenue
3,768,297
3,044,433
2,892,095
Unusual Expense (Income)
NOPBT
634,523
1,085,321
975,828
NOPBT Margin
14.41%
26.28%
25.23%
Operating Taxes
171,678
183,614
204,790
Tax Rate
27.06%
16.92%
20.99%
NOPAT
462,845
901,706
771,038
Net income
461,509
-27.32%
634,984
-33.15%
949,803
-17.73%
Dividends
(151,102)
(659,252)
(3,019,929)
Dividend yield
4.14%
15.03%
75.21%
Proceeds from repurchase of equity
(9,530)
(429,077)
(206,226)
BB yield
0.26%
9.78%
5.14%
Debt
Debt current
1,033,051
40,151
31,619
Long-term debt
38,281
1,041,420
1,064,016
Deferred revenue
Other long-term liabilities
53,664
42,883
33,635
Net debt
(50,674)
376,828
(125,762)
Cash flow
Cash from operating activities
594,873
423,871
270,090
CAPEX
(136,583)
(213,636)
(186,451)
Cash from investing activities
1,003
234,178
732,847
Cash from financing activities
(178,613)
(1,174,702)
(3,313,363)
FCF
492,550
982,906
860,771
Balance
Cash
1,122,006
704,744
1,221,396
Long term investments
Excess cash
901,865
498,256
1,028,000
Stockholders' equity
2,239,073
1,708,659
1,930,237
Invested Capital
2,540,408
2,630,459
2,182,108
ROIC
17.90%
37.47%
35.80%
ROCE
18.43%
34.69%
30.40%
EV
Common stock shares outstanding
107,328
107,939
107,939
Price
34.00
-16.32%
40.63
9.22%
37.20
-23.61%
Market cap
3,649,141
-16.79%
4,385,560
9.22%
4,015,330
-33.12%
EV
3,599,425
4,763,346
3,890,524
EBITDA
828,695
1,263,936
1,145,096
EV/EBITDA
4.34
3.77
3.40
Interest
75,576
75,379
75,949
Interest/NOPBT
11.91%
6.95%
7.78%